Chronic hepatitis C (HCV) infection affects 0.8-1.0% of the UK population, with up to 70% having ongoing chronic infection. HCV is curable but if left untreated can progress to end stage liver disease and potentially hepatocellular carcinoma. HCV management options have changed dramatically over the past five years, with improvement in cure rates and tolerability; cure rates of more than 90% can now be achieved. The main risk factors for acquiring HCV infection in the UK are injecting drug use and sharing drug using equipment. Other risk factors include receipt of blood products in the UK before 1991; tattooing or acupuncture with non-sterile equipment; medical procedures; needlestick injuries and contact with blood from an infected person....
Around 80% of hepatitis C virus (HCV) infections in England are among injecting drug users (IDUs). T...
Hepatitis C infection is a major cause of chronic liver disease and death throughout the world. Hepa...
Primary goals of the Hepatitis C Action Plan for Scotland Phase II (May 2008-March 2011) were to inc...
Chronic hepatitis C (HCV) infection affects 0.8-1.0% of the UK population, with up to 70% having ong...
Background: As direct acting antiviral (DAA) therapy is progressively rolled out for patients with h...
Hepatitis C virus (HCV) infection is a key cause of liver disease but can be cured in more than 95% ...
Hepatitis C infection It is estimated that 0.5–1% of the UK population is infected with hepatitis C ...
In the United States, chronic hepatitis C virus (HCV) infection affects an estimated 3 million perso...
Hepatitis C virus (HCV)-related morbidity and mortality will continue to rise unless HCV testing and...
Hepatitis C virus (HCV) is a major public health problem and a leading cause of chronic liver diseas...
We estimated the extent of undiagnosed hepatitis C virus (HCV) infection in injecting drug users (ID...
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. It a...
In 2003 an estimated 37,500 of Scotland's population was chronically infected with HCV; 44% were und...
Abstract Background As direct acting antiviral (DAA) therapy is progressively rolled out for patient...
Individuals infected with hepatitis C virus (HCV) need to be diagnosed well before developing end-st...
Around 80% of hepatitis C virus (HCV) infections in England are among injecting drug users (IDUs). T...
Hepatitis C infection is a major cause of chronic liver disease and death throughout the world. Hepa...
Primary goals of the Hepatitis C Action Plan for Scotland Phase II (May 2008-March 2011) were to inc...
Chronic hepatitis C (HCV) infection affects 0.8-1.0% of the UK population, with up to 70% having ong...
Background: As direct acting antiviral (DAA) therapy is progressively rolled out for patients with h...
Hepatitis C virus (HCV) infection is a key cause of liver disease but can be cured in more than 95% ...
Hepatitis C infection It is estimated that 0.5–1% of the UK population is infected with hepatitis C ...
In the United States, chronic hepatitis C virus (HCV) infection affects an estimated 3 million perso...
Hepatitis C virus (HCV)-related morbidity and mortality will continue to rise unless HCV testing and...
Hepatitis C virus (HCV) is a major public health problem and a leading cause of chronic liver diseas...
We estimated the extent of undiagnosed hepatitis C virus (HCV) infection in injecting drug users (ID...
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. It a...
In 2003 an estimated 37,500 of Scotland's population was chronically infected with HCV; 44% were und...
Abstract Background As direct acting antiviral (DAA) therapy is progressively rolled out for patient...
Individuals infected with hepatitis C virus (HCV) need to be diagnosed well before developing end-st...
Around 80% of hepatitis C virus (HCV) infections in England are among injecting drug users (IDUs). T...
Hepatitis C infection is a major cause of chronic liver disease and death throughout the world. Hepa...
Primary goals of the Hepatitis C Action Plan for Scotland Phase II (May 2008-March 2011) were to inc...